Frontier Bets $52m On Potential Rival To Gilead's Veklury

 
• By Dexter Jie Yan
  
COVID antiviral intravenous infusion
Bofutrelvir (FB2001) is expected to fill the void of no small molecule-based antiviral treatment for hospitalized COVID-19 patients in China. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia